Small-molecule agonists and antagonists of P2RY13 remain at the preclinical stage, so our data primarily support P2RY13 as an exploratory drug target and mechanistic link between metabolic dysregulation and plaque biology in T2DM-related atherosclerosis. Here, P2RY13 is linked to type 2 diabetes mellitus.